Staff testing in care homes for older people: policy implications for early stages of future pandemic responses

Lily O'Brien[1], Oliver Stirrup[2], Catherine Henderson[3], James Blackstone[4], Natalie Adams[5], Borscha Azmi[5], Lavinia Bertini[6], Jackie Cassell[6], Dorina Cadar[7], Andrew Copas[2], Christopher Finn McQuaid[1], Paul Flowers[8], Laura Shallcross[5], Lara Goscé[1,2]

[1]Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK

[2]Institute for Global Health, UCL, London, UK

[3]Care Policy and Evaluation Centre, London School of Economics and Political Science, UK

[4]Clinical Trials Unit, University College London, London, UK

[5]Institute of Health Informatics, Faculty of Pop Health Sciences, UCL, London, UK

[6]Department of Primary Care and Public Health, Brighton and Sussex Medical School, Brighton, UK

[7]CEDAR Lab, Centre for Dementia Studies, Department of Clinical Neuroscience, Brighton and Sussex Medical School, Brighton, UK

[8]Department of Psychological Sciences & Health, University of Strathclyde, Glasgow, UK

17

18

19

20

Abstract

Background: Care home residents are at high risk of severe outcomes following respiratory infection due to age, co-morbidities, and close contact with staff and other residents. Frequent staff testing could potentially reduce respiratory infection cases in residents, but evidence is limited. This study uses historical COVID-19 data in England to assess the impact of varying staff testing rates under different transmission scenarios to inform response during future pandemics.

Methods: We developed a compartmental model of SARS-CoV-2 transmission in England, with three population strata: general population, care home staff, and residents. The model was calibrated using prevalence data from January 2021 to March 2022 and testing rates from the VIVALDI Study (ISRCTN14447421). We conducted a scenario analysis projecting resident cases and deaths over 12 months under varying staff testing frequencies (monthly, twice-monthly, weekly, twice-weekly, daily) assuming a new dominant strain. We also explored the impact of testing when combined with a hypothetical low-cost highly-effective public health and social measures.

Findings: Staff testing alone has little impact on reducing cases and deaths in the resident population. Daily testing could avert only 3.8% (95%UI: 3.1-4.4%) cases and 3.5% (95%UI: 2.3-4.4%) deaths compared to a baseline testing of less than one test per month. When combined with public health and social measures, however, the effect is large. Daily staff testing, combined with public health and social measures, can reduce resident cases by 54% (95%UI: 50-58%) and

deaths by 50% (95%UI: 26-59%). Additionally, if testing frequency is reduced but there is still a public health and social measure, the effect size decreases, however there are potential cost savings (£0.7 to £3.4 million).

Interpretation: Increasing staff testing alone is insufficient to significantly reduce SARS-CoV-2 cases and deaths in care home residents. However, combining testing with some form of a public health and social measure aimed at reducing transmission among residents, is epidemiologically effective and cost-effective in most scenarios and possibly cost saving.

Introduction

Over a quarter of a million individuals aged 65 and above live in care homes in England and Wales [1] with many affected by comorbidities that increase their risk of poor outcomes. Care homes face high risks of disease outbreaks due to several factors, including the challenges of social distancing in shared living spaces and communal areas, and frequent contact required between staff and residents for daily care. Between March 2020 and May 2021, 24.3% of deaths of care homes residents had been attributed to COVID-19 in England and Wales, with 42,341 total deaths involving COVID-19 being registered [2]. It is essential that care homes can function safely and efficiently during future pandemics to protect vulnerable residents and care home staff. COVID-19 vaccinations were made available to high-risk groups, including care home residents and staff, from December 2020 [2], providing protection against the virus. However, before the introduction of vaccines in England, care homes faced high cases and deaths amongst residents. This illustrates the importance of having robust policies and procedures in place to minimise disruptions to the care home sector; protecting vulnerable populations especially at the beginning of a new respiratory pandemic when pharmaceutical interventions may not be available yet.

While several studies have examined intervention strategies in care homes [3-5] the findings vary regarding the most effective approaches to minimising resident cases and deaths, with some studies recommending asymptomatic staff testing every 3 days [3] and others every 7 to 10 days [4]. Additionally, some research highlights the importance of

pharmaceutical interventions such as vaccination, illustrating its increased efficacy over staff testing [6] and others emphasise the importance of other public health and social measures such as isolating positive cases [4], personal protective equipment (PPE), improved ventilation and contact tracing. It is crucial to determine the best strategies for outbreak control, while also understanding the associated economic costs and quality of life of residents, to guide policy decisions in future pandemics.

In this study, we aim to assess possible testing policies to be adopted during future pandemics. To do so, we used COVID-19 as a case study and developed a compartmental model simulating SARS-CoV-2 transmission in care homes in England. While we modelled COVID-19, due to it being the latest pandemic and having available data, the model is adaptable to similar respiratory infections and could be highly informative in future pandemics, including avian influenza (in case of human-to-human transmission) or emerging mpox variants. The aim of our study is to provide evidence for effective testing protocols that can enable early detection and infection control in vulnerable populations such as care homes. We compared a baseline scenario with three intervention strategies to determine the optimal frequency of staff testing and assess its effectiveness when combined with a public health and social measure. Additionally, we took associated testing and hospitalisation costs into account and estimated the economic impact of these interventions in the form of incremental costs per case averted.

Methods

Model Overview

We developed a compartmental model to simulate the transmission of SARS-CoV-2 in England, stratifying the population into three distinct groups: the general population, care home staff, and care home residents. The general population encompasses all individuals in England who are not classified as care home staff or residents, including all age groups. Care home staff are defined as individuals aged 18 and over who work in care homes in direct contact with residents, while care home residents are aged 65 and above. The model considers a cohort comprising 10,000 senior care home residents and estimated 13,350 staff members by calculating the ratio of staff and occupied beds (~1:1.3) from the VIVALDI Study (ISRCTN14447421) [7].

The Vivaldi-CT trial which informed this analysis began in January 2023 and was developed in close collaboration with care providers. Engagement events with a diverse range of care home staff and sector representatives helped shape the trial intervention “Test to Care”, supporting twice-weekly LFD testing for COVID-19 in care homes. Discussions with care providers addressed the acceptability and uptake of testing and acted as a platform to raise concerns about potential implications for staff members and organisations involved in the trial. Feedback informed the testing protocol. However, due to lower than anticipated COVID-19 case numbers, the trial was stopped early. Here, we use mathematical modelling to simulate the original trial design and assess how it might perform in the early stages of a future pandemic.

A critical assumption of our model is that care homes operate at full capacity, with new residents replacing those who have died. Because we want our model to be informative of the first stages of a new pandemic, we assume that residents are unvaccinated and lack long-term immunity from previous infections. Additionally, to reflect the restriction in visitations allowed at the beginning of the COVID-19 pandemic, we assume that while staff interact with the general population, residents, and other staff, residents only interact with staff and fellow residents. Consequently, the primary routes of SARS-CoV-2 ingress into the care home setting are via staff or new residents, excluding visitors or contractors. This model thus reflects a pandemic scenario restricted to internal transmission within the care home environment. We based this assumption on observations from the COVID-19 pandemic, during which contact between care homes and the outside world was significantly restricted to mitigate transmission risks. We acknowledge however that these restrictions may differ for future pandemics, which could affect the applicability of our findings.

The model, which employs a susceptible-exposed-infectious-recovered (SEIR) framework, was coded using R (v4.3.3) and calibration was performed through the History Matching and Emulation (hmer) package [8-9]which uses Bayes Linear

emulation and history matching, The model was calibrated to observed COVID-19 prevalence rates in the general population [10]and care home residents [7] between January 2021 and March 2022. Full parametrisation, as well as model schematic, equations, and calibration, can be found in the supplementary document.

Following calibration, we split our model into a baseline scenario and different intervention scenarios, with testing rates and the implementation of an additional public health and social measure differing between them. Due to new strains differing in terms of infectiousness and mortality [11], the objective was to consider a new strain to inform policy making for future pandemics. Therefore, we modelled a new hypothetical strain that is both more infectious and more deadly. We then estimated resident cases and death for the following 12 months.

Intervention scenarios

We evaluated three intervention scenarios against a baseline, as shown in Table 1. The baseline scenario assumes that staff members are tested less than once a month (~0.6), in order to represent a hypothetical baseline situation where only symptomatic individuals are required to test. Intervention 1 scenarios, instead, consider the following five testing regimes: (a) monthly, (b) twice a month, (c) once a week, (d) twice a week and (e) daily testing of all staff. In all scenarios, lateral flow tests (LFT) for staff were assumed to have perfect sensitivity, meaning any positive result was treated as a true positive, with staff immediately self-isolating until recovery. The model was designed to study a pandemic period, so we

also modelled two additional intervention scenarios that consider a hypothetical continuous public health and social measure aimed at reducing infection transmission among residents. Intervention 2 considers baseline testing plus a public health and social measure, while intervention 3 combines intervention 1 (the five testing regimens) and intervention 2 (the public health and social measure). To estimate the maximum possible impact of staff testing, we assumed that this hypothetical public health and social measure leads to no infection transmission among residents, whilst transmission between staff and residents is possible. All interventions are described in Table 1.

Table 1: Intervention scenarios and description

Intervention scenario	**Description**
Baseline	Staff are tested less than once a month (~0.6 tests per month per staff member)
Intervention 1	Staff are tested either (a) once a month, (b) twice a month, (c) once a week, (d) twice a week or (e) daily
Intervention 2	Baseline testing with a public health and social measure

Intervention 3	Staff are tested either (a) once a month, (b) twice a month, (c) once a week, (d) twice a week or (e) daily, in conjunction with a public health and social measure

For every intervention, and testing frequency within the intervention, we calculated numbers of resident cases and deaths observed and compared them to the baseline scenario estimating numbers of cases and deaths averted.

Health economic analysis

We associated testing costs and hospitalisation costs with the epidemiological modelling results. No costs are accounted for the public health and social measure. Testing and hospitalisation costs were accounted for in each intervention scenario (including baseline) and were associated to the modelling output ‘cases averted’, which differed depending on the testing strategy and the inclusion of a hypothetical public health and social measure. Testing costs included LFT costs, staff sick pay, and agency backfill. Staff sick pay and agency backfill costs were sourced from audit data provided by the UCL Comprehensive Clinical Trials Unit (CCTU) collected during the VIVALDI-CT [12] factoring in the average duration of staff absences. The unit costs for LFTs were obtained from the United Kingdom Health Security Agency (UKHSA) [13]. LFT costs were multiplied by the total number of care home staff assumed in the model over a 12-month period. As each scenario required different testing frequencies, the number of LFTs performed varied by the intervention (e.g. in the case of monthly testing, 13,350 tests each month over a 12-month period are assumed to be performed). Staff

145 sick pay and agency backfill costs were calculated based on the number of staff self-isolating over the 12 months, which
146 also differed across intervention scenarios. The average cost per staff member (averaging over mean costs per home)
147 was *per episode* following a positive test. Only shifts that were reimbursed by UKHSA were counted. This was a sample
148 of 24 care homes representing 180 staff members with COVID-related sickness. These costs—sick pay, agency backfill,
149 and LFTs—were then combined to determine the total cost per intervention. All costs are reported in 2022-23 pounds (£).

150 Hospitalisation costs were calculated for each intervention and were divided into critical care and non-critical care costs.
151 Resident hospitalisations were estimated from our model output, by multiplying the number of individuals who become
152 infected with SARS-CoV-2 for each intervention, by the proportion of cases requiring either critical or non-critical care. As
153 the aim of this analysis is to estimate the cost-effectiveness of the aforementioned testing interventions during the first
154 stages of a new pandemic, the hospitalisation rates were based upon a report from Ferguson et al. (2020) [14] who
155 estimated the severity of COVID-19 cases by age-group during the first wave of the pandemic in England (however we
156 also acknowledge that in reality some residents requiring hospitalisation will not necessarily access these facilities).
157 Critical and non-critical care costs were obtained from the National Institute for Health and Care Excellence (2023)[15]. All
158 cost data is reported in the technical appendix. Due to the theoretical nature of interventions 2 and 3, we do not consider
159 public health and social measure associated costs, which may include costs such as increased cleaning, re-rostering of
160 staff, provisions of face masks, etc. and thus could not be included in this analysis.

161 Following this we performed a cost-effectiveness analysis by estimating the incremental cost of the interventions
162 (compared to baseline) over the number of cases averted. The ICER is shown below as incremental cost per case
163 averted:

164 $$\frac{C_{int} - C_{bas}}{N_{bas} - N_{int}}$$

165 Where C_{int} and N_{int} are respectively the cost and the number of cases incurred by one of the interventions, and C_{bas} and
166 N_{bas} are costs and cases at baseline.

167 Due to some interventions having ranges crossing zero, we also calculated the probabilities of these interventions being
168 cost saving. For every run of the model, we calculated how many were cost saving compared to the baseline.

169 Sensitivity analysis

170 To account for imperfect performance of the test, a sensitivity analysis was undertaken on the diagnostic sensitivity of the
171 LFTs and is described in the supplementary material. For each of the 803 model runs, a random value between 68% and
172 76% was selected to represent the estimated sensitivity of LFTs [16] . The proportion of resident cases and deaths, as
173 well as costs related to resident hospitalisation, staff testing, and quarantine, were then calculated.

174 Results

175 Fig 1 displays the percentage of resident cases and deaths averted compared to the baseline scenario over a 12-month
176 period, for each intervention. Modelling results show that testing alone (intervention 1) has limited epidemiological impact
177 in reducing cases and deaths. During the twelve-month run time, daily staff testing alone averted up to 3.8% (95%UI: 3.1-
178 4.5%) of resident cases and 3.5% (95%UI: 2.3-4.4%) of resident deaths compared to the baseline testing scenario.
179 Similarly, baseline testing with a public health and social measure (intervention 2) also showed limited impact, by reducing
180 up to 7.4% (95%UI: 5.7-9.2%) cases and 7.0% (95%UI: 5.2-9.0%) deaths compared to baseline testing alone.
181 Contrastingly, the two interventions combined led to a decrease of more than 20% in cases and deaths when testing of
182 staff was performed at least twice a week, with maximum impact of 53.6% (95%UI: 49.5-57.7%) cases and 49.9%
183 (95%UI: 26.3-59.1%) deaths averted by daily testing, when compared to baseline.

184

185

186 **Fig 1: Percentage of cases and deaths averted for each intervention with 95% uncertainty interval (UI).**
187 Intervention 1: Staff are tested once a month, twice a month, once a week, twice a week and daily. Intervention 2:
188 Baseline testing rates with a hypothetical public health and social measure that prevents the transmission of the infection
189 between residents. Intervention 3: Staff are tested once a month, twice a month, once a week, twice a week and daily, in
190 conjunction with the hypothetical public health and social measure. Increased staff testing alone is not enough to visibly

191 reduce the number of cases and deaths in the resident population compared to baseline. Similarly, a public health and
192 social measure alone has also a limited epidemiological impact. However, combining testing and public health and social
193 measures can lead to a ~20% reduction in cases and deaths, in the case of weekly testing, ~30% reduction with twice-
194 weekly testing, or up to ~60% reduction with daily testing.

195

196 Following the epidemiological analysis, total costs were calculated for each intervention over the whole 12-month
197 implementation period (Table 2) and associated with the model epidemiological results (Fig 1). The analysis shows that
198 testing-only strategies (intervention 1) are costly, with total incremental costs ranging from £0.6 to £22 million over a 12-
199 month period. In contrast, baseline, monthly or twice-a-month testing when combined with a hypothetical public health and
200 social measure (interventions 2, 3a, 3b) dominate the baseline strategy, leading to significant cost savings compared to
201 baseline testing without a public health and social measure, with savings ranging from £0.7 to £3.4 million. These savings
202 are attributed to a reduction in resident hospitalisations and no public health and social measure related implementation
203 costs. This means that the combined baseline/monthly/bi-monthly testing plus a public health and social measure strategy
204 would be cost-saving only in situations where the cost of implementing the public health and social measure was no
205 higher than £3.4 million. More frequent testing strategies, such as weekly and twice-a-week testing combined with public
206 health and social measures, may have less substantial cost savings than less frequent testing strategies, but are cost-
207 effective compared to baseline due to the larger number of cases averted, and have high probabilities of also being cost-

saving (96.6% and 89.4%, respectively); however, this depends on the cost of the public health and social measure. In contrast, intervention 3 with daily testing is more expensive than baseline in most cases, but it may be cost-effective as it leads to strong reductions in cases and deaths. Thus, any decision on its implementation is up to policy makers depending on account of resource availability.

The sensitivity analysis results showed a similar trend to that observed in Fig 1, with Intervention 3 (twice-weekly and daily staff testing) consistently averting the highest number of cases and deaths compared to lower testing frequencies and the staff-only intervention. The epidemiological impact decreased with reduced test sensitivity (up to 13% fewer cases and 27% fewer deaths averted for daily testing combined with public health and social measures). Although significant epidemiological impact was observed even at test sensitivities between 68% and 76%, these findings demonstrate the importance of using high-sensitivity tests. Test sensitivity also significantly influenced the cost-effectiveness of interventions. While three interventions were cost-saving under the assumption of perfect test sensitivity, this number decreased to two when sensitivity was reduced. Twice-weekly testing combined with public health and social measures, which appeared potentially cost-saving under perfect test sensitivity assumptions, was not cost-saving in the sensitivity analysis. These findings highlight the influence of test sensitivity on both epidemiological outcomes and economic evaluations. Further details are provided in the Supplementary Appendix.

225 **Table 2: Interventions and associated costs**

226 Table 2 displays hospitalisation, intervention and total costs for all interventions, including baseline. Intervention costs
227 comprise LFT tests, staff sick pay and backfill. Hospitalisation costs comprise non-critical and critical care. Intervention
228 and hospitalisation costs are combined to give an overall cost for each intervention and are compared to the baseline. All
229 costs are in 2022-23 millions of pounds (£).

230

Intervention	**Intervention costs (£ million)**	**Hospitalisation costs (£ million)**	**Total costs (£ million)**	**Costs averted (baseline costs minus intervention costs) (£ million)**
Baseline testing	2.0 (95% UI: 1.7; 2.5)	36.2 (95% UI: 29.9; 44.1)	38.2 (95% UI: 31.6; 46.4)	
Once a month testing	2.8 (95% UI: 2.3; 3.4)	36.1 (95% UI: 29.8; 44.0)	38.9 (95% UI: 32.2; 47.3)	-0.7 (95% UI: -0.9; -0.6)
Twice a month testing	4.5 (95% UI: 3.7; 5.5)	35.9 (95% UI: 29.6; 43.8)	40.4 (95% UI: 33.5; 49.0)	-2.2 (95% UI: -2.7; -1.8)

Once a week testing	6.9 (95% UI: 5.8; 8.3)	35.7 (95% UI: 29.4; 43.4)	42.6 (95% UI: 35.3; 51.6)	-4.3 (95% UI: -5.2; -3.7)
Twice a week testing	10.4 (95% UI: 9.0; 12.0)	35.3 (95% UI: 29.1; 43.1)	45.7 (95% UI: 38.2; 55.0)	-7.5 (95% UI: -8.6; -6.6)
Daily testing	24.4 (95% UI: 22.7; 26.5)	34.9 (95% UI: 28.7; 42.5)	59.2 (95% UI: 51.5; 68.8)	-21.0 (95% UI: -22.4; -19.9)
Baseline testing with public health and social measure	2.0(95% UI: 1.7; 2.5)	33.6 (95% UI: 27.5; 41.2)	35.6 (95% UI: 29.1; 43.5)	2.7 (95% UI: 2.0; 3.4)
Once a month testing with public health and social measure	2.8 (95% UI: 2.3; 3.4)	33.1 (95% UI: 27.0; 40.7)	35.9 (95% UI: 29.4; 44.1)	2.3 (95% UI: 1.5; 3.1)
Twice a month testing with public	4.5 (95% UI: 3.7; 5.5)	32.0 (95% UI: 26.0; 39.4)	36.5 (95% UI: 29.9; 45.0)	1.7 (95% UI: 0.7; 2.7)

health and social measure				
Once a week testing with public health and social measure	6.9 (95% UI: 5.8; 8.3)	30.0 (95% UI: 24.1; 37.2)	36.9 (95% UI: 30.2; 45.6)	1.3 (95% UI: -0.07; 2.7)
Twice a week testing with public health and social measure	10.4 (95% UI: 9.0; 12.0)	26.6 (95% UI: 21.2; 33.6)	37.0 (95% UI: 30.4; 45.6)	1.2 (95% UI: -0.5; 2.9)
Daily testing with public health and social measure	24.4 (95% UI: 22.7; 26.5)	16.9 (95% UI: 12.9; 22.2)	41.2 (95% UI: 35.7; 48.5)	-3.0 (95% UI: -5.4; 0.3)

231

232 Fig 2 presents the cost-effectiveness plane for the various intervention strategies. Interventions 2 and 3 are shown to be
233 less costly in most instances and successful at averting resident cases. However, daily testing under intervention 3,
234 despite averting a significant number of resident cases, may result in higher costs than the baseline scenario.

235

236

237 **Fig 2: Cost-effectiveness plane as Incremental costs per COVID-19 cases averted over 12 months.** Health
238 outcomes (resident cases averted) are plotted on the X axis and incremental costs in millions (£) are plotted on the Y axis.
239 Each point represents incremental costs over cases averted for each model run compared to the baseline scenario.
240 Interventions 2 and 3 (with monthly, twice a month, weekly and twice a week testing) are cost-saving in most cases and
241 always cost-effective. The cost-effectiveness of Intervention 3 with daily testing, however, depends on resource
242 availability.

243 Discussion

244 We presented a compartmental model simulating SARS-CoV-2 transmission in care homes for older adults in England to
245 ascertain the impact of staff testing interventions on resident cases and deaths. We further explored the associated costs
246 for each intervention to provide policy makers with grounded evidence to aid their decision-making for future pandemics.

247 The results of the study demonstrate that staff testing alone is not enough to evidence any substantial reductions in cases
248 and deaths in the resident population. Daily testing without a public health and social measures averted only 3.8%
249 (95%UI: 3.1-4.5%) cases and 3.5% (95%UI: 2.3-4.4%) deaths when compared to baseline. However, regular staff testing,
250 when paired with public health and social measures such as resident zoning, using PPE, contact tracing or improved
251 room ventilation, is the most effective strategy for reducing resident cases and deaths. Our results showed that during the
252 early phase of a pandemic (emerging virus, no prior immunity, no vaccination) 26.6% (95%UI: 23.2-30.4%) resident cases
253 and 25% (95%UI: 14.2-30.7%) resident deaths could be averted with twice-weekly testing of staff and 53.6% (95%UI:
254 49.5-57.7%) resident cases and 49.9% (95%UI: 26.3-59.1%) resident deaths with daily testing, combined with a
255 hypothetical public health and social measure that prevents transmission among residents. Furthermore, monthly, twice-
256 monthly, weekly and twice-weekly testing, when combined with public health and social measures, are cost-effective and
257 most likely cost-saving interventions, and can lead to up to ~£3.4 million costs saved compared to baseline over 12
258 months. These cost savings are due to a consistent reduction in hospitalisations in residents. On the other hand, daily
259 testing combined with public health and social measures is a costly intervention, where the high cost of frequent testing
260 appears to outweigh the financial benefits from fewer hospitalisations (up to £5.3 million additional costs compared to
261 baseline). However, due to the high number of cases and deaths that this intervention can avert, we cannot make
262 definitive conclusions on its cost-effectiveness, and any policy decisions should take resource availability into account.

Our epidemiological results align with several other studies, which suggest public health and social measures—such as personal protective equipment (PPE), zoning of symptomatic cases, and improved room ventilation—can be used alongside staff testing to maximise the prevention of cases and deaths[3-4]Click or tap here to enter text.. It is crucial to carefully consider the type of public health and social measure implemented in conjunction with staff testing to ensure residents' well-being is respected. Zoning within care homes may offer a practical solution for containing infections; however, its effectiveness will depend on factors such as the facility's layout and available staff. While our findings emphasise the importance of public health and social measures alongside staff testing in reducing infections, future guidelines must also prioritise compassion. Full resident isolation is unlikely to be the optimal approach moving forward.

Our epidemiological results also differ from studies such as McGarry et al. (2023) [16] who demonstrated that increased surveillance testing of staff members was associated with meaningful reductions in COVID-19 cases and deaths among residents- especially before vaccine availability.

When it comes to the frequency of testing, our results align with the findings of Gómez Vázquez et al. [5] who also modelled testing interventions in care homes and reported that increasing testing frequency to every three days led to a significant reduction in infections and hospitalisations. On the other Hand, Nguyen et al.[4], recommend staff testing be carried out every 7 to 10 days, explaining that although more frequent testing intervals result in improved outcomes, this may be costly and not feasible. Whilst our results do show daily testing may be more costly than the baseline scenario, we

279 also illustrated how twice-weekly testing may be cost-saving and always cost-effective. Additionally, while more frequent
280 testing could increase workload, time pressures and discomfort associated with testing, our study has factored in the
281 sickness pay and backfill costs for staff required to isolate. This demonstrates that it is economically feasible to test as
282 frequently as twice-weekly, although it is important to note that the costs of testing, backfill and sickness pay were borne
283 by the government rather than care providers during the COVID-19 pandemic.

284 Our model has several strengths. This is the first study able to estimate the cost per case averted of different testing
285 scenarios, which is important from a policy-making perspective. Additionally, our analysis is grounded in real data, having
286 parametrised the model using actual rates of COVID-19 in care homes for older adults in England as observed during the
287 VIVALDI study [7] in 2021-2022. At the same time, the scenario and sensitivity analyses allow us to look beyond the case
288 of COVID19 and make our results informative for future pandemics.

289 Our study also has several limitations. Firstly, due to lack of available data, we could only consider a hypothetical public
290 health and social measure and were not able to explore specific interventions aimed at reducing transmission among
291 residents, such as partial or total resident zoning, resident testing, the use of face masks, or improved room ventilation.
292 This affects both our epidemiological and economic results as we could not consider the costs of these interventions
293 which should be explored in future research. We were, however, able to estimate thresholds on the maximum cost these
294 public health and social measures should have for the combined testing plus public health and social measure strategies

295 to be cost saving. Furthermore, due to the lack of available data, we parameterised the model with transmission rates
296 during the beginning of the vaccination campaign- despite focusing our work on pre-vaccination. Our baseline is therefore
297 representative of the first stages of a vaccine campaign where 38.4% of the population had a first vaccine by the 18th of
298 March [17]. This will likely underestimate the impact of interventions before vaccinations are in place. Chen et al.
299 demonstrated that testing in care homes was highly cost-effective - 3.5 times more cost-effective prior to vaccination
300 rollout [18].

301 Secondly, because our goal was to study a best-case scenario in order to estimate the maximum possible impact of
302 testing strategies, we assumed perfect sensitivity. However, to address real-world conditions, we also conducted a
303 sensitivity analysis (see Supplementary Appendix) using the actual sensitivity of LFT tests. This analysis demonstrated
304 that each intervention prevents fewer cases and deaths and is less cost-effective under realistic conditions. These
305 findings illustrate the importance of developing high-sensitivity tests to maximise epidemiological and economic outcomes.

306 Finally, our model was designed to represent an emergency scenario during the first stages of a new pandemic or a new
307 viral strain of an existing infection. For this reason we made some strong assumptions: (i) we did not include visits from
308 relatives or health professionals in our model. This may not be the case in future pandemic as more recent guidance set
309 out by the UKHSA reinforces the importance of allowing care home residents contacts with friends and relatives [19] Our
310 assumption is however supported by Rosello et al. [3] who estimated the importation of SARS-CoV-2 by visitors to be

negligible. (ii) We also assumed that contact patterns between staff and residents remained constant throughout the simulation, but these patterns may change during an outbreak. (iii) We assumed no vaccine protection.

Assuming no protection from vaccination is reasonable in the context of care homes' preparedness to future pandemics. However, to inform the management of COVID-19 and other infections for which vaccines are already available, it would now be beneficial to revisit these findings under varying levels of vaccine protection to assess whether testing frequencies should be adjusted in the context of vaccination. Several studies, including Fosdick et al. [20] and Vilches et al. [21] demonstrated how effective vaccines could be with low testing rates, while Kahn et al. [22] emphasised that vaccines with lower efficacy should be paired with more frequent testing, particularly in the context of waning immunity/need for re-vaccination. Exploring this further—particularly with the economic component of our analysis—could offer valuable insights. Future research could investigate different vaccine efficacies and the corresponding testing rates required, while incorporating the economic considerations that are central to policy decision-making.

Conclusion

The study demonstrates the importance of combining staff testing with public health and social measures in order to reduce cases and deaths in care homes. Frequent asymptomatic staff testing alone has limited impact in reducing resident cases and deaths and is expensive; yet, combined with low-cost and highly effective public health and social

326 measures, it can significantly improve epidemiological outcomes and yield substantial cost savings. Daily testing is the
327 most effective in averting resident cases but may also result in higher costs, highlighting the balance needed between
328 improved health outcomes and the associated financial costs. Biweekly staff testing seems to be the most effective while
329 still being potentially cost saving. Asymptomatic staff testing, combined with public health and social measures was also
330 shown to be superior to public health and social measures with baseline symptomatic testing, demonstrating the
331 importance of testing. It is important to note, however, that decisions around cost effectiveness of testing may change
332 depending on the pathogen. For instance, with a less virulent pathogen, the resulting low rates of hospital admissions may
333 render frequent testing economically unfeasible, or vice versa, worse pathogens that resulted in higher rates of hospital
334 admissions would make the testing interventions here explored even more cost-effective. Despite this, these findings are
335 critical for guiding the rapid implementation of testing strategies, sick pay policies, and agency backfill measures in future
336 public health response. Policy makers must consider the incremental costs associated with each intervention against the
337 reduction of cases and deaths each offers, as well as the availability of resources when preparing for future epidemics
338 and pandemics in care home settings. Furthermore, the challenges surrounding funding for staff testing, sick pay, and
339 backfill due to increased testing and the inclusion of public health and social measures will need to be addressed,
340 including determining whether the responsibility lies with care providers, the NHS, or the Government.

341 # Reference List

342 1. Office for National Statistics. Older people living in care homes in 2021 and changes since 2011. 2023.

343 2. Office for National Statistics. Deaths involving COVID-19 in the care sector, England and Wales: deaths registered
344 between week ending 20 March 2020 and week ending 2 April 2021. 2021.

345 3. Rosello A, Barnard RC, Smith DRM, Evans S, Grimm F, Davies NG, et al. Impact of non-pharmaceutical
346 interventions on SARS-CoV-2 outbreaks in English care homes: a modelling study. BMC Infect Dis. 2022 Dec
347 1;22(1):324.

348 4. Nguyen LKN, Howick S, McLafferty D, Anderson GH, Pravinkumar SJ, Van Der Meer R, et al. Evaluating
349 intervention strategies in controlling coronavirus disease 2019 (COVID-19) spread in care homes: An agent-based
350 model. Infect Control Hosp Epidemiol. 2021 Sep 14;42(9):1060–70.

351 5. Vilches TN, Nourbakhsh S, Zhang K, Juden-Kelly L, Cipriano LE, Langley JM, et al. Multifaceted strategies for the
352 control of COVID-19 outbreaks in long-term care facilities in Ontario, Canada. Prev Med (Baltim). 2021
353 Jul;148:106564.

354 6. Krutikov M, Bone D, Stirrup O, Bruton R, Azmi B, Fuller C, et al. VIVALDI Cohort Profile: Using linked, routinely
355 collected data and longitudinal blood sampling to characterise COVID-19 infections, vaccinations, and related
356 outcomes in care home staff and residents in England. Wellcome Open Res. 2024 Aug 19;8:553.

357 7. Scarponi D, Iskauskas A, Clark RA, Vernon I, McKinley TJ, Goldstein M, et al. Demonstrating multi-country
358 calibration of a tuberculosis model using new history matching and emulation package - hmer. Epidemics. 2023
359 Jun;43:100678.

360 8. Iskauskas A, Vernon I, Goldstein M, Scarponi D, McKinley TJ, White RG, et al. Emulation and History Matching
361 using the hmer Package. 2022 Sep 12;

362 9. UK Health Security Agency. 2022. REACT-1 studies: monthly results.

363 10. Webster HH, Nyberg T, Sinnathamby MA, Aziz NA, Ferguson N, Seghezzo G, et al. Hospitalisation and mortality
364 risk of SARS-COV-2 variant omicron sub-lineage BA.2 compared to BA.1 in England. Nat Commun. 2022 Oct
365 13;13(1):6053.

366 11. Adams N, Stirrup O, Blackstone J, Krutikov M, Cassell JA, Cadar D, et al. Shaping care home COVID-19 testing
367 policy: a protocol for a pragmatic cluster randomised controlled trial of asymptomatic testing compared with
368 standard care in care home staff (VIVALDI-CT). BMJ Open. 2023 Nov 14;13(11):e076210.

369 12. UKHSA. Personal Communication.

370 13. Ferguson N, et al. Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and
371 healthcare demand. 2020.

372 14. National Institute for Health and Care Excellence. Multiple Technology Appraisal Therapeutics for people with
373 COVID-19 [ID4038]. 2023.

374 15. Krishnamoorthy A, Chandrapalan S, JalayeriNia G, Hussain Y, Bannaga A, Lei II, et al. Influence of seasonal and
375 operator variations on diagnostic accuracy of lateral flow devices during the COVID-19 pandemic: a systematic
376 review and meta-analysis. Clinical Medicine. 2023 Mar;23(2):144–50.

377 16. McGarry BE, Gandhi AD, Barnett ML. Covid-19 Surveillance Testing and Resident Outcomes in Nursing Homes.
378 New England Journal of Medicine. 2023 Mar 23;388(12):1101–10.

379 17. Gómez Vázquez JP, García YE, Schmidt AJ, Martínez-López B, Nuño M. Testing and vaccination to reduce the
380 impact of COVID-19 in nursing homes: an agent-based approach. BMC Infect Dis. 2022 Dec 19;22(1):477.

381 18. GOV.UK. Vaccine update: issue 318, March 2021. 2021.

382 19. Chen S, Creswell R, Hounsell R, Cantrell L, Bajaj S, Dahal P, et al. Mass testing for discovery and control of
383 COVID-19 outbreaks in adult social care: an observational study and cost-effectiveness analysis of 14 805 care
384 homes in England. BMJ Public Health. 2025 Jan 28;3(1):e001376.

385 20. UK Health Security Agency. Supporting safer visiting in care homes during infectious illness outbreaks. 2024.

386 21. Fosdick BK, Bayham J, Dilliott J, Ebel GD, Ehrhart N. Model-based evaluation of policy impacts and the continued
387 COVID-19 risk at long term care facilities. Infect Dis Model. 2022 Sep;7(3):463–72.

22. Vilches TN, Nourbakhsh S, Zhang K, Juden-Kelly L, Cipriano LE, Langley JM, et al. Multifaceted strategies for the control of COVID-19 outbreaks in long-term care facilities in Ontario, Canada. Prev Med (Baltim). 2021 Jul;148:106564.

23. Kahn R, Holmdahl I, Reddy S, Jernigan J, Mina MJ, Slayton RB. Mathematical Modeling to Inform Vaccination Strategies and Testing Approaches for Coronavirus Disease 2019 (COVID-19) in Nursing Homes. Clinical Infectious Diseases. 2022 Mar 1;74(4):597–603.


Percentage of Cases Averted Compared to No Intervention
Percentage of Cases Averted
60
40
20
0
Once a month
Twice a month
Once a week
Bi-weekly
Daily
Baseline testing
Once a month
Twice a month
Once a week
Bi-weekly
Daily
Testing Rate
Intervention
1
2
3
Percentage of Deaths Averted Compared to No Intervention
Percentage of Deaths Averted
60
40
20
0
Once a month
Twice a month
Once a week
Bi-weekly
Daily
Baseline testing
Once a month
Twice a month
Once a week
Bi-weekly
Daily
Testing Rate
Intervention
1
2
3

Fig1


CE plane
Incremental Costs in millions (£)
Cases Averted
-5
0
5
10
15
20
25
-1000
0
1000
2000
3000
4000
5000
Intervention 1 - Once a month
Intervention 1 - Twice a month
Intervention 1 - Once a week
Intervention 1 - Twice a week
Intervention 1 - Daily
Intervention 2- Baseline testing
Intervention 3 - Once a month
Intervention 3 - Twice a month
Intervention 3 - Once a week
Intervention 3 - Twice a week
Intervention 3 - Daily

Fig2